GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Rhea-AI Summary
GRI Bio (NASDAQ: GRI) reported year-end $8.2 million in cash and cash equivalents as of December 31, 2025 and raised an additional $6.5 million in January 2026, strengthening the balance sheet to fund operations into Q1 2027. Key clinical highlights include positive Phase 2a topline data for GRI-0621 in idiopathic pulmonary fibrosis, supplemental RNA‑seq and immune phenotype data reinforcing proof‑of‑concept, and advancement of GRI-0803 toward IND‑enabling studies for autoimmune indications.
Positive
- Cash position of approximately $8.2 million at 12/31/2025
- Raised $6.5 million in January 2026 via At The Market offering
- Positive Phase 2a topline data for GRI-0621 in IPF
- GRI-0803 advanced toward IND-enabling studies
Negative
- Net loss of $12 million for year ended 12/31/2025
- Research and development expenses increased by $3.0 million year-over-year
- Cash runway only expected to fund operations into Q1 2027
News Market Reaction
On the day this news was published, GRI gained 1.54%, reflecting a mild positive market reaction. Argus tracked a peak move of +35.4% during that session. Argus tracked a trough of -8.8% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $58K to the company's valuation, bringing the market cap to $4M at that time. Trading volume was very high at 3.4x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GRI fell 9.09% while key peers showed mixed moves: ADTX -7.01%, APVO -8.03%, PALI +2.47%, TTNP -3.96%, XBIO -3.38%. Momentum scanner shows OGEN -4.93% and ONCO/ADTX up, pointing to stock‑specific pressure rather than a uniform biotech decline.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Aug 14 | Q2 2024 earnings | Neutral | -7.6% | Q2 2024 results with cash update, offering proceeds and IP, preclinical data. |
| May 13 | Q1 2024 earnings | Neutral | -0.5% | Q1 2024 results with net loss, higher R&D, financing to support programs. |
| Apr 01 | FY 2023 earnings | Neutral | -1.3% | Full year 2023 financial results and corporate update release. |
Earnings and financial updates have repeatedly been followed by modest negative price reactions, suggesting a pattern of post‑earnings selling even when updates emphasize progress and runway extension.
Over recent earnings cycles, GRI Bio has coupled financial reports with pipeline progress. Q1 and Q2 2024 results highlighted advancement of GRI‑0621 and GRI‑0803, new capital raises and runway guidance into Q1 2025. Full‑year 2023 results also produced a small decline. Today’s full‑year 2025 update extends cash runway into Q1 2027 and follows a series of financings and trial readouts, fitting a pattern where operational progress coexists with persistent market skepticism.
Historical Comparison
Past earnings-related releases saw an average move of -3.13%. Today’s -9.09% reaction to FY 2025 results represents a notably larger downside response than prior earnings updates.
Earnings updates progressed from FY 2023 through Q1 and Q2 2024 with modest moves, while today’s FY 2025 report emphasizes stronger cash resources and a runway extended into Q1 2027, reflecting a shift from shorter-term funding visibility to a longer operational horizon.
Regulatory & Risk Context
An effective Form S-3 shelf filed on 2026-01-29 allows GRI Bio to offer up to $250,000,000 of securities over time. A related 424B5 prospectus supports at-the-market sales of up to $60,000,000 in common stock, with proceeds designated for general corporate purposes, working capital and other administrative needs.
Market Pulse Summary
This announcement underscores GRI Bio’s focus on balance sheet strength and clinical execution. With cash of $8.2 million, an additional $6.5 million raised, and runway into Q1 2027, the company pairs financial visibility with positive Phase 2a IPF data and IND-enabling work for GRI‑0803. Historical earnings releases have seen modest negative moves, so investors may watch future financings under the $250,000,000 shelf and progress toward later-stage trials.
Key Terms
idiopathic pulmonary fibrosis medical
phase 2a medical
clinical proof-of-concept medical
ind-enabling regulatory
at the market offering financial
AI-generated analysis. Not financial advice.
Company reported
Balance sheet strengthened to fund operations into Q1 2027
Strong Phase 2a clinical data for GRI-0621 in idiopathic pulmonary fibrosis reinforce clinical proof-of-concept and therapeutic differentiation
GRI-0803 focused on autoimmune indications with high unmet need advancing through IND-enabling activities
LA JOLLA, CA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases today summarized recently reported Full Year 2025 financial results, provided an update on the Company’s current cash position and cash runway and summarized key clinical and corporate highlights.
“In 2025, we prioritized disciplined clinical execution and balance sheet strength, delivering compelling clinical data from our lead IPF program which underscores the therapeutic differentiation of GRI-0621,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio. “Entering 2026 with a strong cash position, we are focused on advancing GRI-0621 in IPF, progressing GRI-0803 toward the clinic and executing our clinical strategy with capital discipline to drive long-term value creation.”
Recent Highlights
- Raised approximately
$14.5 in gross proceeds in December 2025 and January 2026 - Strong cash position expected to fund planned operations into the first quarter of 2027
- Announced positive Phase 2a topline data from the completed Phase 2a clinical study of GRI-0621 in idiopathic pulmonary fibrosis
- Reported additional data demonstrating suppression of pro-fibrotic immune phenotypes, reinforcing topline data and clinical proof-of-concept
- Generated new RNA-sequencing gene expression data demonstrating direct impact on the core biology of fibrosis and lung repair
- Advanced plans to progress GRI-0803 into IND-enabling studies, expanding the Company’s pipeline in autoimmune disease
Summary of Financial Results for the Year Ended December 31, 2025
As of December 31, 2025, the Company had cash and cash equivalents of approximately
Net loss was
Research and development expenses were
General and administrative expenses were
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of key immune cells, such as Natural Killer T (“NKT”) cells, earlier in the inflammatory cascade to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an Immunomodulator and anti-fibrotic RARβγ agonist shown to inhibit the activity of key immune cells, like iNKT cell activity, along with anti-fibrotic and epithelial cell repair activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of serious autoimmune diseases with significant unmet need. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the Company’s expectations with respect to development and commercialization of the Company’s product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies, topline or interim data or trials will be indicative of results of later studies or clinical trials or final data, that final data will be indicative of a proof-of-concept, the Company’s beliefs and expectations regarding potential shareholder value and future financial performance, the Company’s beliefs about the timing and outcome of regulatory approvals and potential regulatory approval pathways, the Company’s expected future milestones, shareholder value and the length of time the Company’s current resources will fund its planned operations (which current estimate assumes only initial preparatory activities for GRI-0621 as substantial additional capital or resources will be required to fund a Phase 2b clinical trial of GRI-0621). Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company’s common stock on The Nasdaq Capital Market and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company’s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company’s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) that later data or clinical trials may be inconsistent with or contrary to data and observations to date, including that later data may not indicate a proof-of-concept or patient benefit; (10) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents and its ability to obtain any expected patent term extensions, adjustments, exclusivities or disclaimers; and (12) other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on January 30, 2026 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
FAQ
What cash and runway did GRI Bio (GRI) report on February 4, 2026?
What were the Phase 2a results for GRI-0621 reported by GRI Bio (GRI)?
How did GRI Bio (GRI) change research and development spending in 2025?
What is the status of GRI-0803 according to GRI Bio (GRI)?
How material was GRI Bio's 2025 net loss and what drove it?
